Entera Bio Ltd.
ENTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001638097
No open-market purchases or sales by Entera Bio Ltd. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $19.0M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +1 vs. previous quarter
- 27
- 13F valueReported value at the end of Q2 2026
- $19.0M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ENTX, Q2 2026
No superinvestor reported holding ENTX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Entera Bio Ltd. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2026 (view filing) | Mar 9 | 2 days | Germano Geno JDirector | PPurchaseOrdinary Shares, par value NIS 0.0000769 per share | +20.0K | $1.30 | +$26.0K | +100.0%40.0K after | |
| Mar 9, 2026 (view filing) | Mar 5 | 4 days | Ellis SeanDirector | PPurchaseOrdinary Shares, par value NIS 0.0000769 per share | +10.0K | $1.23 | +$12.3K | +5.6%188.1K after | |
| Feb 17, 2026 (view filing) | Feb 12 | 5 days | Rubin Steven DDirector | PPurchaseOrdinary Shares, par value NIS 0.0000769 per share | +5.00K | $1.49 | +$7.45K | +50.0%15.0K after | |
| Feb 11, 2026 (view filing) | Feb 10 | 1 day | Taitel HayaDirector | PPurchaseOrdinary Shares, par value NIS 0.0000769 per share | +7.50K | $1.48 | +$11.1K | – | |
| Feb 11, 2026 (view filing) | Feb 10 | 1 day | Germano Geno JDirector | PPurchaseOrdinary Shares, par value NIS 0.0000769 per share | +20.0K | $1.49 | +$29.8K | – | |
| Feb 11, 2026 (view filing) | Feb 9 | 2 days | Rubin Steven DDirector | PPurchaseOrdinary Shares, par value NIS 0.0000769 per share | +10.0K | $1.20 | +$12.0K | New position10.0K after | |
| Feb 11, 2026 (view filing) | Feb 9 | 2 days | Ellis SeanDirector | PPurchaseOrdinary Shares, par value NIS 0.0000769 per share | +18.0K | $1.24 | +$22.3K | +11.2%178.1K after | |
| Dec 30, 2025 (view filing) | Dec 29 | 1 day | Toledano Miranda JayneChief Executive Officer | PPurchaseOrdinary Shares, par value NIS 0.0000769 per share | +11.0K | $1.81 | +$19.9K | +2.6%426.6K after | |
| Jan 16, 2024 (view filing) | Jan 12 | 4 days | Taitel HayaDirector | PPurchaseOrdinary Shares, par value NIS 0.0000769 per share | +9.50K | $0.99 | +$9.40K | +37.1%35.1K after | |
| Jan 11, 2024 (view filing) | Jan 10 | 1 day | Taitel HayaDirector | PPurchaseOrdinary Shares, par value NIS 0.0000769 per share | +7.62K | $0.77 | +$5.86K | +42.3%25.6K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Entera Bio Ltd. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Knoll Capital Management, LLC | 5,881,879 | $10.4M | 4.86% | 00.0% | Unchanged |
| BVF Inc | 2,425,000 | $4.29M | 0.11% | +2,425,000 | New |
| Siren, L.L.C. | 736,457 | $1.30M | 0.03% | +736,457 | New |
| Renaissance Technologies LLC | 368,847 | $652.9K | 0.00% | −104,595−22.1% | Reduced |
| Parkman Healthcare Partners LLC | 274,497 | $485.9K | 0.05% | −14,173−4.9% | Reduced |
| The PNC Financial Services Group, Inc. | 273,031 | $483.3K | 0.00% | +263,031+2,630.3% | Added |
| Seven Fleet Capital Management LP | 191,354 | $338.7K | 0.06% | −14,188−6.9% | Reduced |
| HighTower Advisors, LLC | 74,573 | $132.9K | 0.00% | +37,743+102.5% | Added |
| HRT Financial LP | 72,486 | $128.0K | 0.00% | +56,994+367.9% | Added |
| Schonfeld Strategic Advisors LLC | 58,871 | $104.2K | 0.00% | +3,648+6.6% | Added |